Related Experiment Videos
Methylphenidate protocol: feasibility in a pediatric practice
Clinical Pediatrics
|December 1, 1991
Summary
Double-blind trials of methylphenidate for attention deficit disorder (ADD) in pediatric practices are feasible. While many children did not benefit, the study design aids in assessing medication response.
Area of Science:
- Pediatric Practice
- Clinical Trial Design
- Pharmacological Treatment
Background:
- Attention deficit disorder (ADD) is a common diagnosis in children.
- Assessing medication efficacy in general pediatric settings presents challenges.
- Methylphenidate is a commonly prescribed medication for ADD.
Purpose of the Study:
- To evaluate the feasibility of conducting double-blind, placebo-controlled methylphenidate trials in a general pediatric practice.
- To assess the therapeutic benefit of methylphenidate in children diagnosed with attention deficit disorder.
- To determine the suitability of this trial methodology for private pediatric practices.
Main Methods:
- A three-week protocol involving baseline, methylphenidate, and placebo weeks.
- Utilized Connors rating scales completed by parents and teachers for assessment.
- Employed a double-blind, randomized crossover design with medication/placebo order unknown to participants and investigator.
Main Results:
- Initial pilot phase showed a 53% trial completion rate, improved to 83% with modifications.
- 43% of children identified as hyperactive did not show benefit from methylphenidate.
- Discrepancies in parent and teacher ratings occurred in six trials.
Conclusions:
- Double-blind trials for methylphenidate in attention deficit disorder are feasible in general pediatric practices.
- The methodology, despite some challenges, aids in assessing individual medication response.
- The study design is adaptable for evaluating ADHD treatments in community-based pediatric settings.